CD8A and cancer: Personalized vaccines can induce and activate CD4 + T helper 1 cells and CD8 + T cells to target neoantigens and kill cancer cells, resulting in the release of cancer antigens and positively promoting the “cancer-immunity cycle” [140] (Fig. 4E).